NEW YORK (GenomeWeb News) – Cellular Dynamics International today said that it has signed a deal to supply the Nestlé Institute of Health Sciences with its iCell and MyCell product lines.

The iCell portfolio includes cardiomyocytes, neurons, hepatocytes, endothelial cells, and other cell types in development, while the MyCell line includes cell products manufactured from donor samples using iPSC technology to make stem cells or differentiated cells from any individual.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.